Mesoblast (NASDAQ:MESO) Shares Gap Up – Here’s What Happened

Shares of Mesoblast Limited (NASDAQ:MESO) gapped up prior to trading on Friday . The stock had previously closed at $18.69, but opened at $19.84. Mesoblast shares last traded at $19.78, with a volume of 94,779 shares.

Wall Street Analysts Forecast Growth

MESO has been the topic of a number of research analyst reports. Cantor Fitzgerald raised Mesoblast to a “strong-buy” rating in a report on Thursday, January 30th. Jefferies Financial Group lowered Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. Finally, Piper Sandler reiterated an “overweight” rating and issued a $24.00 price objective (up previously from $15.00) on shares of Mesoblast in a research note on Friday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Mesoblast presently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Mesoblast Stock Up 4.6 %

The firm has a 50-day moving average of $16.33 and a two-hundred day moving average of $10.92. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.

Institutional Investors Weigh In On Mesoblast

Several hedge funds have recently made changes to their positions in MESO. R Squared Ltd acquired a new position in shares of Mesoblast in the 4th quarter valued at $30,000. Lindbrook Capital LLC grew its holdings in Mesoblast by 70.9% during the 4th quarter. Lindbrook Capital LLC now owns 2,172 shares of the company’s stock worth $43,000 after acquiring an additional 901 shares during the last quarter. Signaturefd LLC raised its stake in shares of Mesoblast by 128.7% in the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after acquiring an additional 3,099 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Mesoblast by 22.1% during the fourth quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock worth $133,000 after purchasing an additional 1,213 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in Mesoblast in the 4th quarter valued at $134,000. Institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.